Exhibit 99.1
ADMA Biologics Reports Record Second Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments
Achieved Record Total Revenues of $17.8 Million in Second Quarter 2021, a 129% Increase Over Second Quarter 2020
Narrowed Gross and Net Losses Year-over-Year
ADMA Now Anticipates Exiting 2021 Approaching an Annualized Revenue Run Rate of Approximately $100 Million or More; Reiterates All Previously Communicated Strategic
and Financial Objectives
Management to Host Conference Call and Webcast Today at 4:30 p.m. ET
RAMSEY, NJ and BOCA RATON, FL – August 11, 2021 – ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics,
today reported financial results for the three months ended June 30, 2021, its fiscal second quarter, and provided an overview of recent progress and accomplishments.
“ADMA continues to achieve milestones and execute on its commercial and operational strategies as
evidenced by the strong second quarter financial results and regulatory successes. The totality of the year-to-date accomplishments across business segments has the Company well-positioned to sustain quarter-over-quarter revenue growth with
improving margins for the foreseeable future,” said Adam Grossman, President and Chief Executive Officer of ADMA.
“Less than two years into ADMA’s
commercial launch of its intravenous immune globulin (“IVIG”) product portfolio, the Company generated record quarterly revenues of $17.8 million, representing an increase of 129% year-over-year. This top-line growth is particularly impressive
in light of the pandemic-related headwinds that continue to persist throughout the product launch period, which impacted industry supply chains and limited engagement with physicians and providers. Additionally, these results do not reflect
the substantial benefits anticipated from the recently approved BIVIGAM® expanded production scale, increasing our facility’s total annual peak production capacity from 400,000 liters to 600,000 liters, as well as the expected
approval of the VanRx SA25 Workcell aseptic fill-finish machine (“VanRx”) in the second half of 2021. We are confident that our underlying business trends have demonstrated strength and resilience year-to-date and can continue improving in the
second half of 2021 and beyond as operating efficiencies materialize and production ramp-up further progresses.
“ADMA has also seen a substantial strengthening of its supply chain in the first half of the year. The recent receipt of zero Form 483 observations as a part of the
pre-approval inspection (“PAI”) for the VanRx machine paves the way for an anticipated approval over the coming months. When approved, it will cap a multi-year remediation and end-to-end supply chain initiative at the Boca Raton, FL manufacturing
facility, and will propel ADMA into an elite group of U.S.-based drug manufacturers with comprehensive in-house control of a majority of its critical manufacturing functions.
1
“The ADMA BioCenters team, through
its year-to-date accomplishments, has made significant strides towards ensuring uninterrupted raw material plasma supply. The enhanced yield anticipated from the recent implementation of Haemonetics’ Persona® technology, the
extension of the Company’s primary third-party plasma supply contract to the end of 2022 and the continued expansion of the BioCenters plasma collection network establishes a solid foundation for ADMA to ensure continuity of product supply into
an increasingly supply-constrained immune globulin market. With the current industry-wide pressures on plasma collection operations, ADMA’s strategic emphasis on building an internal collection network and solidifying third-party supplemental
supply should yield significant returns in the periods ahead and largely insulate the Company from supply and pricing fluctuations.
“Over the past 4 years, ADMA has also been diligently building a vertically integrated commercial biologics manufacturing organization since acquiring its manufacturing
facility and assets in June 2017 and is now successfully emerging from its multi-year investment, regulatory and remediation phase. The majority of substantive investments are now in the rearview, the wholly owned manufacturing plant is now
fully remediated and collectively, positions the Company to meet or exceed all longer-term financial targets. These accomplishments could not have been realized without the dedication and focus of ADMA’s staff, leadership and advisors. We commend
the entire team for their extraordinary efforts focused on improving healthcare for U.S. patients,” concluded Mr. Grossman.
Select Second Quarter 2021 Achievements & Recent Corporate Developments:
| • |
Continued Commercial Execution: Achieved second quarter 2021 total revenues of $17.8 million, compared to $7.8 million for the second quarter of 2020, reflecting a 129% increase.
|
| • |
Successful PAI Paves the Way for Second Half 2021 VanRx Approval. We anticipate the successfully completed PAI, during which the U.S. Food and Drug Administration (FDA) issued no Form 483 observations, will facilitate a VanRx approval over the
coming months. In addition to the significant operating efficiencies expected to result from the expected VanRx approval, the fill-finish capabilities will propel ADMA into an elite class of U.S. drug manufacturers with complete
end-to-end control of critical manufacturing functions. As previously stated, we are actively evaluating new business opportunities with these fill-finish capabilities and intend to update the market as appropriate.
|
| • |
On Track BioCenters Network Expansion. ADMA currently has eight plasma collection facilities under its corporate umbrella at various stages of approval and development, including five facilities that are currently operational and collecting plasma. The
Company remains on track to achieve its stated goal of operating 10 or more plasma collection centers by 2024. Over the remainder of 2021, ADMA anticipates receiving approval for one facility presently pending a Biologics License
Application (“BLA”) and expects to file BLAs for two additional plasma collection centers.
|
| • |
Expanded Suite of IG Product Offerings with Introduction of Additional Vial Sizes. The availability of the additional NABI-HB® and BIVIGAM® vial sizes meaningfully enhance ADMA’s go-to-market offering for its immunoglobulin product portfolio and allows for more
versatile utilization by providers and patients.
|
Second Quarter 2021 Financial Results
Total revenues for the quarter ended June 30, 2021, were approximately $17.8 million, compared to approximately $7.8 million for the quarter ended June 30, 2020,
representing an increase of approximately $10.0 million, or 129%. The revenue growth for the quarter ended June 30, 2021, compared to the quarter ended June 30, 2020, was favorably impacted by the continued commercial ramp-up of ADMA’s IVIG
product portfolio.
Consolidated net loss for the quarter ended June 30, 2021 was approximately $18.9 million, or $(0.15) per basic and diluted share, compared to a consolidated net loss
of approximately $20.2 million, or $(0.23) per basic and diluted share, for the quarter ended June 30, 2020. The $1.3 million narrowing in net loss compared to the prior year period was primarily attributable to increased revenues and improved
gross margins. The net loss incurred during the second quarter of 2021 includes a one-time, non-recurring charge related to a separation and transition agreement in the amount of approximately $0.8 million.
At June 30, 2021, ADMA had cash and cash equivalents of approximately $42.4 million and accounts receivable of approximately $23.5 million, compared to cash and cash
equivalents of approximately $75.8 million and accounts receivable of approximately $6.5 million as of June 30, 2020. ADMA’s net working capital as of June 30, 2021 was approximately $153.2 million, compared to approximately $130.1 million as of
June 30, 2020.
Conference Call Information
ADMA will host a conference call today, August 11, 2021, at 4:30 p.m. Eastern Time, to discuss the fiscal second quarter 2021 financial results and recent corporate
updates. To access the conference call, please dial (855) 884-8773 (local) or (615) 622-8043 (international) at least 10 minutes prior to the start time and refer to conference ID 8992329. A live audio webcast of the call will be available
under "Events & Webcasts" in the Investor section of the Company's website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available on the Company's website approximately two hours after the event.
About BIVIGAM®
BIVIGAM® (immune globulin intravenous, human – 10% liquid) is a plasma-derived, polyclonal, intravenous immune globulin (IVIG). BIVIGAM® was
approved by the FDA in May 2019 and is indicated for the treatment of primary humoral immunodeficiency (PI), including, but not limited to the following group of genetic disorders: X-linked and congenital agammaglobulinemia, common variable
immunodeficiency, Wiskott-Aldrich syndrome and severe combined immunodeficiency. BIVIGAM® contains a broad range of antibodies similar to those found in normal human plasma. These antibodies are directed against bacteria and viruses
and help to protect PI patients against serious infections. BIVIGAM® is a purified, sterile, ready-to-use preparation of concentrated human Immunoglobulin antibodies. Certain data and other information about BIVIGAM® or
ADMA and its products can be found on the Company’s website at www.admabiologics.com.
About Nabi-HB®
Nabi-HB® is a hyperimmune globulin that is rich in antibodies to the Hepatitis B virus. Nabi-HB® is a purified human polyclonal antibody product
collected from plasma donors who have been previously vaccinated with a Hepatitis B vaccine. Nabi-HB® is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (HBsAg), prenatal exposure to
infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute Hepatitis B virus infection. Hepatitis B is a potentially life-threatening liver infection caused by the Hepatitis B
virus. It is a major global health problem and can cause chronic infection and put people at high risk of death from cirrhosis and liver cancer. Nabi-HB® has a well-documented record of long-term safety and effectiveness since its
initial market introduction. Certain data and other information about Nabi-HB® or ADMA and its products can be found on the Company’s website at www.admabiologics.com.
About ADMA BioCenters
ADMA BioCenters operates FDA-licensed facilities specializing in the collection of human plasma used to make special medications for the treatment and prevention of
diseases. Managed by a team of experts who have decades of experience in the specialized field of plasma collection, ADMA BioCenters provides a safe, professional and pleasant donation environment. ADMA BioCenters strictly follows FDA regulations
and guidance and enforces current good manufacturing practices (cGMP) in all of its facilities. For more information about ADMA BioCenters, please visit www.admabiocenters.com.
About ADMA Biologics, Inc. (ADMA)
ADMA is an end-to-end American commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the
treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three FDA-approved plasma-derived biologics for the treatment of immune deficiencies and the
prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of
PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the Hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located
in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to
manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who
suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and
product candidates. For more information, please visit www.admabiologics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995 about ADMA Biologics, Inc. and its subsidiaries (collectively, “we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or
imply future results, performance or achievements, and may contain such words as “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “should,” “could,” “would,” “may,” or, in each
case, their negative, or words or expressions of similar meaning. These forward-looking statements also include, but are not limited to, statements about ADMA’s future results of operations, including our anticipated timing for reaching
profitability and our expected revenue run rates, meaningful gross margin improvement and operating efficiencies; the impact of COVID-19 on the Company’s financial results and business operations; expected benefits from the VanRx aseptic
fill-finish machine, including cost efficiencies and contract manufacturing opportunities; the anticipated benefits from the recent implementation of Haemonetics’ Persona® technology combined with our plasma collection network;
BIVIGAM®’s production capacity; the goal of building and opening new plasma collection centers by 2024; the Company’s plasma collections and production; our ability to maintain plasma supply; the outcome and timing of our BLA
application for our new plasma centers and for FDA approval of our VanRx aseptic fill-finish machine; and the expected benefits of additional NABI-HB® and BIVIGAM® vial sizes. Actual events or results may differ materially
from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will
prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking
statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements,
including, but not limited to, the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.
COMPANY CONTACT:
Skyler Bloom
Director, Investor Relations and Corporate Strategy | 201-478-5552 |sbloom@admabio.com
INVESTOR RELATIONS CONTACT:
Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 | michelle@argotpartners.com
ADMA BIOLOGICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
|
Three Months Ended June 30,
|
||||||||
|
2021
|
2020
|
|||||||
|
REVENUES:
|
||||||||
|
Product revenue
|
$
|
17,794,881
|
$
|
7,751,885
|
||||
|
License revenue
|
35,709
|
35,709
|
||||||
|
Total revenues
|
17,830,590
|
7,787,594
|
||||||
|
OPERATING EXPENSES:
|
||||||||
|
Cost of product revenue (exclusive of amortization expense shown below)
|
18,832,624
|
13,495,629
|
||||||
|
Research and development
|
1,158,866
|
1,656,420
|
||||||
|
Plasma center operating expenses
|
2,803,326
|
877,902
|
||||||
|
Amortization of intangible assets
|
178,838
|
178,838
|
||||||
|
Selling, general and administrative
|
10,438,168
|
8,702,630
|
||||||
|
Total operating expenses
|
33,411,822
|
24,911,419
|
||||||
|
LOSS FROM OPERATIONS
|
(15,581,232
|
)
|
(17,123,825
|
)
|
||||
|
OTHER INCOME (EXPENSE):
|
||||||||
|
Interest income
|
5,926
|
19,411
|
||||||
|
Interest expense
|
(3,246,680
|
)
|
(3,067,306
|
)
|
||||
|
Other expense
|
(83,317
|
)
|
(6,371
|
)
|
||||
|
Other expense, net
|
(3,324,071
|
)
|
(3,054,266
|
)
|
||||
|
NET LOSS
|
$
|
(18,905,303 |
) |
$
|
(20,178,091 |
) |
||
|
BASIC AND DILUTED LOSS PER COMMON SHARE
|
$
|
(0.15
|
)
|
$
|
(0.23
|
)
|
||
|
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
|
||||||||
|
Basic and Diluted
|
127,416,126
|
86,347,467
|
||||||
6
ADMA BIOLOGICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
|
June 30,
2021
|
December 31,
2020
|
|||||||
|
ASSETS
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
42,408,958
|
$
|
55,921,152
|
||||
|
Accounts receivable, net
|
23,544,594
|
13,237,290
|
||||||
|
Inventories
|
99,699,743
|
81,535,599
|
||||||
|
Prepaid expenses and other current assets
|
5,701,863
|
3,046,466
|
||||||
|
Total current assets
|
171,355,158
|
153,740,507
|
||||||
|
Property and equipment, net
|
46,486,980
|
41,593,090
|
||||||
|
Intangible assets, net
|
2,086,445
|
2,444,121
|
||||||
|
Goodwill
|
3,529,509
|
3,529,509
|
||||||
|
Right to use assets
|
6,829,040
|
4,259,191
|
||||||
|
Deposits and other assets
|
2,526,660
|
2,106,976
|
||||||
|
TOTAL ASSETS
|
$
|
232,813,792
|
$
|
207,673,394
|
||||
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
6,167,465
|
$
|
11,073,708
|
||||
|
Accrued expenses and other current liabilities
|
11,490,239
|
8,365,143
|
||||||
|
Current portion of deferred revenue
|
142,834
|
142,834
|
||||||
|
Current portion of lease obligations
|
385,858
|
365,682
|
||||||
|
Total current liabilities
|
18,186,396
|
19,947,367
|
||||||
|
Senior notes payable, net of discount
|
93,877,017
|
92,968,866
|
||||||
|
Deferred revenue, net of current portion
|
2,047,281
|
2,118,698
|
||||||
|
Lease obligations, net of current portion
|
7,073,415
|
4,334,151
|
||||||
|
Other non-current liabilities
|
36,151
|
54,886
|
||||||
|
TOTAL LIABILITIES
|
121,220,260
|
119,423,968
|
||||||
|
COMMITMENTS AND CONTINGENCIES
|
||||||||
|
STOCKHOLDERS' EQUITY
|
||||||||
|
Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding
|
-
|
-
|
||||||
|
Common Stock - voting, $0.0001 par value, 300,000,000 and 150,000,000 shares authorized, 131,872,026 and 104,902,888 shares issued and outstanding
|
13,187
|
10,490
|
||||||
|
Additional paid-in capital
|
489,330,692
|
428,704,039
|
||||||
|
Accumulated deficit
|
(377,750,347
|
)
|
(340,465,103
|
)
|
||||
|
TOTAL STOCKHOLDERS' EQUITY
|
111,593,532
|
88,249,426
|
||||||
|
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
|
$
|
232,813,792
|
$
|
207,673,394
|
||||
7